Report Sections

See All Reports

Coronavirus Infections (722) Severe Acute Respiratory Syndrome (493) Infection (402) Pneumonia (331) Communicable Diseases (176) Respiratory Distress Syndrome, Adult (161) Acute Lung Injury (126) Respiratory Distress Syndrome, Newborn (126) (114) Syndrome (106) Virus Diseases (85) Pneumonia, Viral (73) Critical Illness (63) Depression (62) Anxiety Disorders (44) Disease (39) Stress Disorders, Post-Traumatic (34) Emergencies (31) Respiratory Tract Infections (31) Inflammation (30) Neoplasms (30) Cardiovascular Diseases (29) Stress Disorders, Traumatic (29) Wounds and Injuries (29) Lung Injury (27) Stress, Psychological (27) Mental Disorders (26) Diabetes Mellitus (25) Hypoxia (25) Depressive Disorder (24) Thrombosis (23) Hypertension (22) Respiratory Tract Diseases (22) Acute Kidney Injury (21) Lung Diseases (21) Disease Progression (18) Olfaction Disorders (18) Embolism (16) Influenza, Human (16) Stroke (16) Arthritis (15) Pulmonary Embolism (15) Respiration Disorders (15) Blood Coagulation Disorders (14) HIV Infections (14) Hemostatic Disorders (14) Thromboembolism (14) Burnout, Psychological (13) Chronic Disease (13) Fibrosis (13) Lung Diseases, Obstructive (13) Multiple Sclerosis (13) Sclerosis (13) Cognitive Dysfunction (12) Diabetes Mellitus, Type 2 (12) Lung Diseases, Interstitial (12) Myocardial Infarction (12) Pulmonary Disease, Chronic Obstructive (12) Pulmonary Fibrosis (12) Respiratory Aspiration (12) Arthritis, Rheumatoid (11) Autism Spectrum Disorder (11) Brain Injuries (11) Chronic Pain (11) Heart Diseases (11) Kidney Diseases (11) Substance-Related Disorders (11) Venous Thrombosis (11) Crohn Disease (10) Diabetes Mellitus, Type 1 (10) Heart Failure (10) Infarction (10) Lung Neoplasms (10) Autistic Disorder (9) Dyspnea (9) Myocarditis (9) Obesity (9) Pneumonia, Ventilator-Associated (9) Pregnancy Complications (9) Brain Injuries, Traumatic (8) Carcinoma (8) Colitis (8) Colitis, Ulcerative (8) Depression, Postpartum (8) Liver Diseases (8) Renal Insufficiency, Chronic (8) Respiratory Syncytial Virus Infections (8) Rheumatic Diseases (8) Ulcer (8) Vitamin D Deficiency (8) Coronary Artery Disease (7) Coronary Disease (7) Dementia (7) Feeding and Eating Disorders (7) Hematologic Neoplasms (7) Infertility (7) Inflammatory Bowel Diseases (7) Kidney Failure, Chronic (7) Parkinson Disease (7) Problem Behavior (7) Pulmonary Valve Insufficiency (7) Venous Thromboembolism (7) Burnout, Professional (6) Collagen Diseases (6) Frailty (6) Immune System Diseases (6) Immunologic Deficiency Syndromes (6) Ischemia (6) Lupus Erythematosus, Systemic (6) Lymphoma (6) Musculoskeletal Pain (6) Overweight (6) Parasomnias (6) Pediatric Obesity (6) Psychotic Disorders (6) RNA Virus Infections (6) Sepsis (6) Shock (6) Spinal Cord Injuries (6) Acute Coronary Syndrome (5) Alcohol Drinking (5) Alcoholism (5) Autoimmune Diseases (5) Breast Neoplasms (5) Carcinoma, Non-Small-Cell Lung (5) Child Development Disorders, Pervasive (5) Convalescence (5) Coronaviridae Infections (5) Cystic Fibrosis (5) Delirium (5) Depressive Disorder, Major (5) Disease Susceptibility (5) Dyssomnias (5) Gastroparesis (5) Hypersensitivity (5) Leukemia (5) Lymphopenia (5) Multiple Organ Failure (5) Myocardial Ischemia (5) Neurologic Manifestations (5) Osteoarthritis (5) Prostatic Neoplasms (5) Renal Insufficiency (5) Alzheimer Disease (4) Asthma (4) Attention Deficit Disorder with Hyperactivity (4) Behavior, Addictive (4) Body Weight (4) Brain Diseases (4) Coinfection (4) Colonic Neoplasms (4) Death (4) Deglutition Disorders (4) Disseminated Intravascular Coagulation (4) Embolism and Thrombosis (4) Fibromyalgia (4) Head and Neck Neoplasms (4) Heart Arrest (4) Hemorrhage (4) Hypertension, Pulmonary (4) Liver Cirrhosis (4) Metabolic Syndrome (4) Migraine Disorders (4) Mycobacterium Infections (4) Neoplasm Metastasis (4) (4) Pancreatic Neoplasms (4) Postoperative Complications (4) Prediabetic State (4) Signs and Symptoms, Respiratory (4) Sjogren's Syndrome (4) Sleep Apnea Syndromes (4) Sleep Initiation and Maintenance Disorders (4) Thrombophilia (4) Vascular Diseases (4) Weight Loss (4) Acquired Immunodeficiency Syndrome (3) Adenoviridae Infections (3) Appendicitis (3) Arrhythmias, Cardiac (3) Arthritis, Psoriatic (3) Asymptomatic Diseases (3) Bronchiectasis (3) Carcinoma, Renal Cell (3) Cardiomyopathies (3) Chilblains (3) Common Cold (3) Cross Infection (3) Dermatitis (3) Developmental Disabilities (3) Digestive System Diseases (3) Dysgeusia (3) Endometriosis (3) Fatigue (3) Fever (3) Gastrointestinal Diseases (3) Giant Cell Arteritis (3) Glucose Intolerance (3) Glucose Metabolism Disorders (3) Hemophilia A (3) Leukemia, Lymphoid (3) Macular Edema (3) Malnutrition (3) Measles (3) Melanoma (3) Metabolic Diseases (3) Mucocutaneous Lymph Node Syndrome (3) (3) Nervous System Diseases (3) Neuroendocrine Tumors (3) Occupational Stress (3) Osteoarthritis, Knee (3) Ovarian Neoplasms (3) Panic Disorder (3) Paramyxoviridae Infections (3) Peripheral Arterial Disease (3) Polymyalgia Rheumatica (3) Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) Pregnancy Complications, Infectious (3) Premature Birth (3) Psychological Trauma (3) Pulmonary Edema (3) Rheumatic Fever (3) ST Elevation Myocardial Infarction (3) Schizophrenia (3) Seizures (3) Sleep Apnea, Obstructive (3) Sleep Wake Disorders (3) Systemic Inflammatory Response Syndrome (3) Taste Disorders (3) Tobacco Use Disorder (3) Triple Negative Breast Neoplasms (3) Ventricular Dysfunction (3) Ventricular Dysfunction, Left (3) Acute Disease (2) Ageusia (2) Agoraphobia (2) Alopecia (2) Alpha 1-Antitrypsin Deficiency (2) Amyotrophic Lateral Sclerosis (2) Anemia, Sickle Cell (2) Angina Pectoris (2) Angioedema (2) Angioedemas, Hereditary (2) Anxiety, Separation (2) Arteritis (2) Asymptomatic Infections (2) Atherosclerosis (2) Atrial Fibrillation (2) Bacterial Infections (2) Behcet Syndrome (2) Bipolar Disorder (2) Caliciviridae Infections (2) Clinical Deterioration (2) Cognition Disorders (2) Colorectal Neoplasms (2) Communicable Diseases, Emerging (2) Compassion Fatigue (2) Compulsive Personality Disorder (2) Congenital Abnormalities (2) Conjunctivitis (2) Dermatitis, Atopic (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Eczema (2) Emphysema (2) Endocrine System Diseases (2) Fatigue Syndrome, Chronic (2) Ganglion Cysts (2) Gastroenteritis (2) Gastroesophageal Reflux (2) Gaucher Disease (2) Glioblastoma (2) Headache (2) Healthcare-Associated Pneumonia (2) Heart Defects, Congenital (2) Heart Failure, Systolic (2) Hematologic Diseases (2) Huntington Disease (2) Hyperglycemia (2) Hyperkinesis (2) Hyperphagia (2) Hypothermia (2) Hypoventilation (2) Idiopathic Pulmonary Fibrosis (2) Intervertebral Disc Degeneration (2) Intestinal Diseases (2) Ischemic Attack, Transient (2) Jaundice (2) Leukemia, Myeloid, Acute (2) Lymphoproliferative Disorders (2) Macular Degeneration (2) Mobility Limitation (2) Mood Disorders (2) Motor Neuron Disease (2) Multiple Myeloma (2) Multiple Sclerosis, Relapsing-Remitting (2) Muscular Dystrophies (2) Mutism (2) Mycoses (2) Myelodysplastic Syndromes (2) Myeloproliferative Disorders (2) Myositis (2) Necrosis (2) Neoplasms, Plasma Cell (2) Nerve Degeneration (2) Neurodevelopmental Disorders (2) Nidovirales Infections (2) Noncommunicable Diseases (2) Nutrition Disorders (2) Obesity, Morbid (2) Obsessive-Compulsive Disorder (2) Oral Manifestations (2) Pain, Postoperative (2) Peripheral Vascular Diseases (2) Phobia, Social (2) Phobic Disorders (2) Pneumonia, Pneumocystis (2) Psoriasis (2) Purpura, Thrombocytopenic, Idiopathic (2) Rare Diseases (2) Recurrence (2) Respiratory Sounds (2) Sarcoidosis (2) Shock, Septic (2) Small Cell Lung Carcinoma (2) Spinal Diseases (2) Sprains and Strains (2) Suicidal Ideation (2) Suicide (2) Tachycardia (2) Thoracic Diseases (2) Thrombocytopenia (2) Toxemia (2) Trauma and Stressor Related Disorders (2) Tuberculosis (2) Urinary Bladder, Overactive (2) Urinary Tract Infections (2) Uterine Cervical Neoplasms (2) Uveitis (2) Vision Disorders (2) Vision, Low (2) Yellow Fever (2) Abruptio Placentae (1) Acalculous Cholecystitis (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Alcohol Drinking in College (1) Alcohol-Related Disorders (1) Alcoholic Intoxication (1) Alveolitis, Extrinsic Allergic (1) Amblyopia (1) Anemia, Aplastic (1) Angina, Stable (1) Anorexia (1) Anorexia Nervosa (1) Aortic Valve Stenosis (1) Apnea (1) Arthritis, Juvenile (1) Aspergillosis (1) Aspergillosis, Allergic Bronchopulmonary (1) Asphyxia Neonatorum (1) Asthenopia (1) Atrioventricular Block (1) Atrophy (1) Autonomic Nervous System Diseases (1) Back Pain (1) Bacteremia (1) Barotrauma (1) Birth Weight (1) Blister (1) Body Weight Changes (1) Bone Diseases, Metabolic (1) Bradycardia (1) Brain Concussion (1) Breast Cancer Lymphedema (1) Bronchial Diseases (1) Bronchiolitis (1) Bronchitis (1) Bronchitis, Chronic (1) Bronchopulmonary Dysplasia (1) Brucellosis (1) Bulimia (1) Calculi (1) Carcinoma, Hepatocellular (1) Carcinoma, Ovarian Epithelial (1) Carcinoma, Small Cell (1) Carcinoma, Squamous Cell (1) Cardiovascular Abnormalities (1) Cataract (1) Celiac Disease (1) Cellulitis (1) Cerebral Hemorrhage (1) Cerebral Palsy (1) Cerebrovascular Disorders (1) Chest Pain (1) Chlamydia Infections (1) Cholangiocarcinoma (1) Cholangitis (1) Cholecystitis (1) Cholecystitis, Acute (1) Chronic Traumatic Encephalopathy (1) Clostridium Infections (1) (1) Colonic Diseases (1) Communication Disorders (1) Compulsive Behavior (1) Consciousness Disorders (1) Constipation (1) Constriction, Pathologic (1) Conversion Disorder (1) (1) (1) Coronary Artery (1) Coronary Stenosis (1) (1) Cough (1) Coxsackievirus Infections (1) Cryopyrin-Associated Periodic Syndromes (1) Deafness (1) Death, Sudden, Cardiac (1) Dental Calculus (1) Dental Plaque (1) Depressi (1) Depressive Disorder, Treatment-Resistant (1) DiGeorge Syndrome (1) Diabetic Nephropathies (1) Diabetic Neuropathies (1) Diphtheria (1) (1) Down Syndrome (1) Dyspareunia (1) Emergence Delirium (1) Encephalitis (1) Endocarditis (1) Endophthalmitis (1) Endotoxemia (1) Enuresis (1) Epilepsy (1) Esophageal and Gastric Varices (1) Esophagitis, Peptic (1) Eye Diseases (1) Eye Infections (1) Fabry Disease (1) Facial Pain (1) Familial Mediterranean Fever (1) Fatty Liver (1) (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fever of Unknown Origin (1) Fistula (1) Food Hypersensitivity (1) Fractures, Closed (1) Fractures, Stress (1) Gait Disorders, Neurologic (1) Genetic Diseases, Inborn (1) Genetic Predisposition to Disease (1) Gestational Weight Gain (1) Gingivitis, Necrotizing Ulcerative (1) Gout (1) (1) Headache Disorders, Secondary (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Failure, Diastolic (1) Heart Murmurs (1) Helminthiasis (1) Hematoma (1) Hematoma, Subdural (1) Hematoma, Subdural, Chronic (1) Hemoglobinopathies (1) Hepatitis (1) Hepatitis A (1) Hepatitis C (1) Hepatitis, Alcoholic (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hodgkin Disease (1) Hyaline Membrane Disease (1) Hyperaldosteronism (1) Hypercapnia (1) Hyperphosphatemia (1) Hyperplasia (1) Hypersensitivity, Immediate (1) Hypertension, Pregnancy-Induced (1) Hypokalemia (1) Hyponatremia (1) Hypoparathyroidism (1) Hypotension (1) Iatrogenic Disease (1) Infant, Newborn, Diseases (1) Infec (1) Infecti (1) Infertility, Female (1) Infertility, Male (1) Intellectual Disability (1) Intestinal Atresia (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Joint Diseases (1) Keratoconjunctivitis (1) Keratosis (1) Keratosis, Actinic (1) Leishmaniasis (1) Leukemia, Lymphocytic, Chronic, B-Cell (1) Leukemia, Myeloid (1) Leukemia, Myelomonocytic, Acute (1) Leukemia, Myelomonocytic, Chronic (1) Liver Cirrhosis, Biliary (1) Liver Failure (1) Low Back Pain (1) Lung (1) Lyme Disease (1) Lymphedema (1) Lymphocytosis (1) Lymphoma, B-Cell (1) Lymphoma, Mantle-Cell (1) Macrophage Activation Syndrome (1) Malaria (1) Maternal Death (1) Maxillofacial Injuries (1) Memory Disorders (1) Meningitis (1) Meningitis, Meningococcal (1) Menorrhagia (1) Menstruation Disturbances (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Molluscum Contagiosum (1) Monoclonal Gammopathy of Undetermined Significance (1) Mouth Diseases (1) Mouth, Edentulous (1) Movement Disorders (1) Mucositis (1) Multiple Chronic Conditions (1) Muscle Spasticity (1) Muscular Atrophy (1) Muscular Dystrophy, Duchenne (1) Myalgia (1) Myocardial Reperfusion Injury (1) Myofascial Pain Syndromes (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplastic Cells, Circulating (1) Nephritis (1) Neurobehavioral Manifestations (1) Neurocognitive Disorders (1) Neuromyelitis Optica (1) Non-alcoholic Fatty Liver Disease (1) Obsessive Behavior (1) Olfactory Nerve Injuries (1) Orbital Cellulitis (1) Osteoarthritis, Hip (1) Osteochondritis (1) Osteomyelitis (1) Otitis Media with Effusion (1) Overweig (1) Pain (1) Pain, Procedural (1) Pancreatitis (1) Paraproteinemias (1) Paresis (1) Peanut Hypersensitivity (1) Perinatal Death (1) Periodontal Diseases (1) Peripheral Nervous System Diseases (1) Peritoneal Neoplasms (1) Pharyngeal Diseases (1) Pleuropneumonia (1) (1) (1) Pneumonia, Bacterial (1) Pneumonia, V (1) Pre-Eclampsia (1) Pregnancy in Diabetics (1) Preleukemia (1) Primary Dysautonomias (1) Prostatic Hyperplasia (1) Protein-Energy Malnutrition (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Aspergillosis (1) Pulmonary Atelectasis (1) Pulmonary Eosinophilia (1) Radiculopathy (1) Rectal Neoplasms (1) Reperfusion Injury (1) (1) (1) Respiratory Distress Sy (1) Respiratory Hypersensitivity (1) Retinal Vein Occlusion (1) Rupture (1) Sarcoidosis, Pulmonary (1) Sarcopenia (1) Schizophrenia Spectrum and Other Psychotic Disorders (1) (1) Scleroderma, Localized (1) Scleroderma, Systemic (1) Self-Injurious Behavior (1) Severe Acute Respiratory Syn (1) Sexually Transmitted Diseases (1) Sexually Transmitted Diseases, Bacterial (1) Shock, Cardiogenic (1) Short Bowel Syndrome (1) Signs and Symptoms, Digestive (1) Skin Abnormalities (1) Skin Diseases (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Sleep Apnea, Central (1) Soft Tissue Neoplasms (1) Somatoform Disorders (1) Spinal Stenosis (1) Spondylarthritis (1) Spondylolisthesis (1) Status Epilepticus (1) Stillbirth (1) Stomatitis (1) Str (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Superinfection (1) Syncope (1) Syncope, Vasovagal (1) Tachycardia, Sinus (1) Tachycardia, Ventricular (1) Temporomandibular Joint Disorders (1) Temporomandibular Joint Dy (1) Temporomandibular Joint Dysfunction Syndrome (1) Thalassemia (1) Thrombophlebitis (1) Torsades de Pointes (1) Tourette Syndrome (1) Trauma, Nervous System (1) Trichuriasis (1) Tuberculosis, Pulmonary (1) Ulce (1) Urinary Bladder, Underactive (1) Urinary Incontinence (1) Urinary Retention (1) Urologic Diseases (1) Urticaria (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Ventricular Dysfunction, Right (1) Virus Dis (1) Von Willebrand Diseases (1) Vulvar Neoplasms (1) Weight Gain (1) Xerostomia (1) beta-Thalassemia (1)

D001068: Feeding and Eating Disorders

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO


Correlated Drug Terms (9)


Name (Synonyms) Correlation
drug929 Counter Attitudinal Therapy Wiki 0.38
drug867 Computer Based Response Training Weight Loss Intervention Wiki 0.38
drug794 Ciclesonide Metered Dose Inhaler [Alvesco] Wiki 0.38
Name (Synonyms) Correlation
drug1399 Generic Response Training Control Intervention Wiki 0.38
drug1707 Interpersonal Therapy Wiki 0.38
drug749 Ceralasertib Wiki 0.38
drug1456 Healthy Weight Program (HW) Wiki 0.38
drug532 Body Project (BP) Wiki 0.38
drug2752 Questionnaires Wiki 0.14

Correlated MeSH Terms (6)


Name (Synonyms) Correlation
D001836 Body Weight Changes NIH 0.38
D002032 Bulimia NIH 0.38
D006963 Hyperphagia NIH 0.27
Name (Synonyms) Correlation
D001835 Body Weight NIH 0.19
D009765 Obesity NIH 0.13
D004194 Disease NIH 0.06

Correlated HPO Terms (3)


Name (Synonyms) Correlation
HP:0100739 Bulimia HPO 0.38
HP:0002591 Polyphagia HPO 0.27
HP:0001513 Obesity HPO 0.13

Clinical Trials

Navigate: Correlations   HPO

There are 7 clinical trials


1 Target Engagement of a Novel Dissonance-Based Treatment for DSM-5 Eating Disorders

Most people with an eating disorder (ED) do not receive good treatment. The investigators have developed a new brief group treatment that is supposed to work by reducing how much women with an ED value the impossible thinness standard promoted by the media and how much they value/crave binge foods. The investigators want to test whether the treatment actually changes those two mechanisms using brain scan data, which is more objective than completing questionnaires and even interviews. In the first phase of the study (R61), the investigators will compare women in the treatment versus those on a wait-list. If the investigators can show that the treatment "works" (does what the investigators think it does) compared to no active treatment (women will be allowed to seek and receive outside help but investigators will not provide it until after the wait-list), investigators will conduct the second phase of study (R33),where they will randomly assign women with an ED to either the new treatment or to a group treatment that represents what many college mental health clinics provide to their clients with ED.

NCT03261050
Conditions
  1. Eating Disorder
Interventions
  1. Behavioral: Counter Attitudinal Therapy
  2. Behavioral: Interpersonal Therapy
MeSH:Disease Feeding and Eating Disorders

Primary Outcomes

Description: Interviewer assesses frequency in binge eating episodes

Measure: Change in occurrences of binge eating episodes using Eating Disorder Diagnostic Interview

Time: Week 8; R33 also reviews at 6-month follow-up

Description: Interviewer assesses frequency of compensatory weight control behaviors

Measure: Change in occurrences of compensatory weight control behavior using Eating Disorder Diagnostic Interview

Time: Week 8; R33 also reviews at 6-month follow-up

Description: Interviewer assesses change in psychosocial impairment

Measure: Change in psychosocial impairment due to eating disorder symptoms using the Clinical Impairment Assessment Questionnaire

Time: Week 8; R33 also reviews at 6-month follow-up

Secondary Outcomes

Description: Assess if CAT produces larger pre-post reductions in reward region in response to thin models and binge food (Not collected during COVID-19 shelter-at-home order)

Measure: Change in reward region of the brain using fMRI

Time: Week 1 and Week 8

Description: Assess if there are any changes in suicide ideation/attempts

Measure: Change in suicidal ideation/attempts using the Patient Health Questionnaire version 9 (PHQ-9)

Time: Weeks 2, 4 and 6

Description: Assess if there are any changes in negative affect

Measure: Change in negative affect using the Positive Affect and Negative Affect Scale-Revised

Time: Weeks 2, 4, and 6

Description: Assess if there are any changes in body dissatisfaction

Measure: Change in body dissatisfaction using the Body Dissatisfaction Scale

Time: Weeks 2, 4 and 6

Description: Assess if there are any changes in food addiction (Only collected during R61 phase)

Measure: Change in food addiction using the Yale Food Addiction Scale version 2.0

Time: Weeks 2, 4, and 6

Description: Assess if there are any changes in valuation of the thin beauty ideal

Measure: Change in valuation of thin ideal using the Thin Ideal Valuation Scale

Time: Weeks 2, 4, 6, and 8; R33 also reviews at 6-month follow-up

Description: Assess if there are any changes in dietary restraint

Measure: Change in dietary restraint using the 10-item Dutch Restrained Eating Scale

Time: Week 8; R33 also reviews at 6-month follow-up

Description: Three implicit association tasks will assess response to binge foods, thin models, and eating disorder behavior words at pre- and post-test (Not collected during COVID-19 shelter-at-home order)

Measure: Change in implicit associations of binge foods, thin models, and eating disorder behavior words

Time: Week 8; R33 also reviews at 6-month follow-up
2 Translational Neuroscience: Response Training for Obesity Treatment

This project will test whether a food response training intervention produces lasting body fat loss, use objective brain imaging to examine the mechanism of effect of this treatment and investigate the generalizability of the training to non-training foods, and examine factors that should amplify intervention effects to provide a test of the intervention theory. This novel treatment represents a bottom-up implicit training intervention that does not rely on executive control, prolonged caloric deprivation, and expensive clinicians to deliver, like behavioral weight loss treatments that have not produced lasting weight loss. If this computer-based response training intervention produces sustained body fat loss in overweight individuals, it could be easily implemented very broadly at almost no expense, addressing a leading public health problem.

NCT03375853
Conditions
  1. Obesity
  2. Hyperphagia
  3. Feeding and Eating Disorders
Interventions
  1. Behavioral: Computer Based Response Training Weight Loss Intervention
  2. Behavioral: Generic Response Training Control Intervention
MeSH:Obesity Hyperphagia Feeding and Eating Disorders
HPO:Obesity Polyphagia

Primary Outcomes

Description: Change in participant's body fat percentage

Measure: Body Fat Change

Time: Baseline, 1 month, 3 months, 6 months, 12 months

Secondary Outcomes

Description: Eating disorder symptoms as measured with the Eating Disorder Diagnostic Interview

Measure: Change in Eating Disorder Symptoms

Time: Baseline, 1 month, 3 months, 6 months, 12 months

Description: Change in Dietary Restraint, Emotional Eating, and External Eating (aggregate score) as measured by the Dutch Eating Behavior Questionnaire

Measure: Dietary Restraint, Emotional Eating, and External Eating

Time: Baseline, 1 month, 3 months, 6 months, 12 months

Description: Chang in Disinhibited Eating as measured by the Three Factor Eating Questionnaire

Measure: Change in Disinhibited Eating Behavior

Time: Baseline, 1 month, 3 months, 6 months, 12 months

Description: Change in Eating When Not Hungry as measured by the Eating in the Absence of Hunger Questionnaire

Measure: Change in Eating in the Absence of Hunger Behavior

Time: Baseline, 1 month, 3 months, 6 months, 12 months

Description: Change in Problematic eating patterns associated with symptoms of addictive behaviors as measured by the Yale Food Addiction Scale

Measure: Change in Food Addiction Behavior

Time: Baseline, 1 month, 3 months, 6 months, 12 months

Description: Change in Physical Activity as measured by the Paffenberger Questionnaire

Measure: Change in Physical Activity

Time: Baseline, 1 month, 3 months, 6 months, 12 months

Description: Change in Substance use frequency (i.e., number of times per day) for alcohol of participants as measured by the Daily Drinking Questionnaire

Measure: Change in Alcohol Use Behavior

Time: Baseline, 1 month, 3 months, 6 months, 12 months

Description: Change in Substance use frequency (i.e., number of times per day) for common recreational drugs of participants as measured by the Daily Drug Taking Questionnaire

Measure: Change in Substance Use Behavior

Time: Baseline, 1 month, 3 months, 6 months, 12 months

Description: Change in Participant behavioral response to food pictures, and subjective palatability rating

Measure: Change in Participant Ratings of Unhealthy Food Palatability

Time: Baseline, 1 month

Description: Change in Participant behavioral response to food pictures, and willingness to pay given dollar amounts (aggregate score) for the pictured food

Measure: Change in Participant Ratings of Food Monetary Value

Time: Baseline, 1 month

Description: Change Participant food craving behaviors as measured by the Food Craving and Liking Scale

Measure: Change in Food Craving and Liking Behavior

Time: Baseline, 1 month, 3 months, 6 months, 12 months

Description: Change in Participant BMI using standard methods of calculation

Measure: Change in Body Mass Index

Time: Baseline, 1 month, 3 months, 6 months, 12 months

Description: Change in mean R-Peak Amplitude measured using three-lead ECG using PowerLab 8 Diagnostic Suite

Measure: Change in mean R-Peak Amplitude

Time: Baseline, 1 month, 3 months, 6 months, 12 months

Description: Change in Heart Rate Variability measured using three-lead ECG using PowerLab 8 Diagnostic Suite

Measure: Change in Heart Rate Variability

Time: Baseline, 1 month, 3 months, 6 months, 12 months
3 Biological Risk Factors for Onset of Binge Eating and Compensatory Behaviors

The purpose of this proposed project is to test whether several biological factors (such as elevated brain reward region and attention region response to high-calorie foods, weaker inhibitory region response to high-calorie foods, habitual caloric deprivation, and elevated limbic region responsivity) increase the risk of problematic eating (bingeing and purging) in female adolescents.

NCT03687346
Conditions
  1. Eating Disorder
MeSH:Bulimia Feeding and Eating Disorders
HPO:Bulimia

Primary Outcomes

Description: Eating Disorder Diagnostic Interview (EDDI)

Measure: Change in binge eating behaviors using the EDDI

Time: 6 months, 1 year, 2 year, and 3 year follow-up

Description: Eating Disorder Diagnostic Interview (EDDI)

Measure: Change in compensatory behaviors using the EDDI

Time: 6 months, 1 year, 2 year, and 3 year follow-up
4 Impact of COVID-19 Lockdown on Severely Obese Patients With or Without Binge Eating Behaviors

COVID-19 lockdown presents particular challenges for people living with obesity. Indeed during this period, the lifestyle was deeply modified: diet, activity, and sleep behaviours, home office, take care of child, social distancing... All of these modifications may have led to stress and anxiety. It has been previously demonstrated that high perceived stress levels are correlated with high preference for sweet and fat foods . In this context caution would be exercised in obese patients especially those with binge eating disorders. Indeed binge eating disorder is characterized by compulsive overeating or consuming abnormal amounts of food while feeling unable to stop and a loss of control. And one key trigger of binge eating disorder is stress and anxiety. Thus, patients with binge eating disorders may have been more sensitive to the impact of lockdown and thus urgently would require appropriated care management. The main objective is to compare the eating behaviour between obese patients with or without binge eating disorders. The second objective is to compare the weight evolution between the two groups before and after the lockdown. To reach these objectives, the scientific team of the CIO project proposes to contact by phone and e-mail obese patients (with or without binge eating disorders) who have been hospitalized for their obesity disease before the start of the lockdown in the Endocrinology department of the Lyon Hospital. The patients will be asked to fill in several questionnaires (using an online tool) allowing to evaluate their mood, anxiety, eating behaviour, binge eating disorders… during the lockdown. The results of these questionnaires will be compared to those collected during their hospitalisation before the lockdown. The hypothesis is that participants suffering from binge eating disorder will have more sever eating behaviour perturbations as higher level of stress, anxiety, depressive symptoms.

NCT04431284
Conditions
  1. Feeding and Eating Disorders
Interventions
  1. Other: Questionnaires
MeSH:Feeding and Eating Disorders

Primary Outcomes

Measure: Comparison of the BMI (kg/m²) evolution between the two groups

Time: Day 21

Measure: Score comparison of the Dutch Eating Behavior Questionnaire

Time: Day 21
5 Impact of Containment Measures in People With Eating Disorders: a Descriptive Study

Since March 17, 2020, the French government has implemented national containment measures due to the COVID-19 epidemic. Quarantine is an unpleasant experience : Separation from relatives, loss of liberty, concern about the infectious status, boredom, can negatively affect mental health, with the emergence of anxiety and depressive symptoms. In addition, confinement can disrupt usual physical activity, a major destabilization criterion for patients suffering from eating disorders (ED). Finally, conditions of confinement can harm social support, yet identified as a protective and resilience factor in stress contexts. Thus, the current context of confinement and social distances could be source of an increase in eating behavior disorders symptoms in people suffering from ED.

NCT04492189
Conditions
  1. Eating Disorders
  2. COVID 19
MeSH:Feeding and Eating Disorders

Primary Outcomes

Description: the investigators aim to investigate the link between containment measures

Measure: Variation in eating disorders

Time: 1 month

Description: the investigators aim to investigate the link between ED symptomatology with EDE-Q (eating disorder evaluation, caractéristiques du TCA)

Measure: Variation in eating disorders

Time: 1 month

Secondary Outcomes

Description: The investigators aim to investigate the link between containment measures

Measure: Vision of the bodily aspect

Time: 1 month

Description: The investigators aim to investigate the link between body dissatisfaction

Measure: Vision of the bodily aspect

Time: 1 month

Description: the investigators aim to investigate the link between containment measures

Measure: Variation in physical activity

Time: 1 month

Description: the investigators aim to investigate the link between physical activity

Measure: Variation in physical activity

Time: 1 month

Description: the investigators aim to investigate the link between containment measures

Measure: Identify the clinical factors modulating the psychological state during confinement

Time: 1 month

Description: the investigators aim to investigate the link between emotional eating

Measure: Identify the clinical factors modulating the psychological state during confinement

Time: 1 month
6 Prevention of Eating Disorders in At-Risk Female Students: Adaptation and Evaluation of Two Interventions in French-Speaking Switzerland

Eating disorders are psychopathologies with serious repercussions on the somatic, psychological and social level. Currently available treatments are unfortunately for now not fully efficient, therefore researchers have recommended to develop prevention initiatives. Until now, no study has been carried out in Switzerland to evaluate the efficacy of an intervention for the prevention of eating disorders. The goal of the present study is to evaluate two eating disorders prevention intervention that have been largely validated in the US, called the Body Project (BP) and the Healthy Weight Program (HW). Both interventions target body dissatisfaction, which is a well-identified risk factor of eating disorders. They will be compared to a one-month waiting list. Because of the pandemic situation due to the Severe Acute Respiratory Syndrome coronavirus (COVID-19), both interventions will be delivered virtually via a collaborative platform. The sessions will be recorded to carry out a quality control. To compare the BP and HW interventions to a waiting list, a three-arm randomized controlled study will be carried out, including female students from French-speaking Switzerland. Recruitment will include 90 participants. Participants will be randomly assigned to one of the three arms of the study. They will be evaluated before (T0) and after (T1) the interventions or the waiting list. Following the interventions, the participants will have one month of follow-up before a final evaluation (T2). Participants on the waiting list will receive the BP following the one-month waiting period and will then be evaluated (T2). After having signed the consent form, the participant will be randomized to one of the three study arms, with a 1: 1: 1 allocation ratio. Interventions will be given in groups of six participants. Randomization will be blocked to ensure groups of equal size, and that groups of six participants for each arm are regularly formed. The blocks will be of variable size (3, 6, 9) to protect the concealment. The hypotheses are as follows: 1. The two interventions BP and HW will have an effect on body dissatisfaction (primary outcome) as well as on the thin-ideal internalization, dietary restraint, negative affect, and eating disorders psychopathology (secondary outcomes), compared to the waiting list; 2. There will be no differences between the BP and the HW on the primary and secondary outcomes; 3. The effects observed thanks to the interventions will be maintained after one month of follow-up.

NCT04558073
Conditions
  1. Body Dissatisfaction
Interventions
  1. Behavioral: Body Project (BP)
  2. Behavioral: Healthy Weight Program (HW)
MeSH:Feeding and Feeding and Eating Disorders

Primary Outcomes

Description: Mean change in Body Dissatisfaction after interventions in comparison with waiting-list

Measure: Mean Change in Body Dissatisfaction on the Body Shape Questionnaire 8C (score ranging from 8 to 48, with higher scores indicating higher body dissatisfaction) from baseline to post-intervention or post-waiting

Time: one month (Month 1)

Secondary Outcomes

Description: Mean change in thin-ideal internalization after interventions in comparison with waiting-list

Measure: Mean Change in Thin-Ideal Internalization on the Socio-Cultural Attitudes Towards Appearance Questionnaire (score ranging from 1 to 5 with higher scores indicating higher thin-ideal internalization) from baseline to post-intervention or post-waiting

Time: one month (Month 1)

Description: Mean change in Dietary Restraint after interventions in comparison with waiting-list

Measure: Mean Change in Dietary Restraint on the Dutch Eating Behaviour Questionnaire (score ranging from 1 to 5 with higher scores indicating higher dietary restraint) from baseline to post-intervention or post-waiting

Time: one month (Month 1)

Description: Mean change in Anxiety after interventions in comparison with waiting-list

Measure: Mean Change in Anxiety on the Hospital Anxiety and Depression Scale (score ranging from 0 to 21 with higher scores indicating higher anxiety) from baseline to post-intervention or post-waiting

Time: one month (Month 1)

Description: Mean change in Depression after interventions in comparison with waiting-list

Measure: Mean Change in Depression on the Hospital Anxiety and Depression Scale (score ranging from 0 to 21 with higher scores indicating higher depression) from baseline to post-intervention or post-waiting

Time: one month (Month 1)

Description: Mean change in Eating Disorders Psychopathology after interventions in comparison with waiting-list

Measure: Mean Change in Eating Disorders Psychopathology on the Eating Disorders Examination-Questionnaire (score ranging from 0 to 6 with higher scores indicating higher eating disorders psychopathology) from baseline to post-intervention or post-waiting

Time: one month (Month 1)

Description: Mean change in Body Dissatisfaction between post-intervention and follow-up

Measure: Mean Change in Body Dissatisfaction on the Body Shape Questionnaire 8C (score ranging from 8 to 48, with higher scores indicating higher body dissatisfaction) from post-intervention to follow-up

Time: one month (Month 2)

Description: Mean change in Thin-Ideal Internalization between post-intervention and follow-up

Measure: Mean Change in Thin-Ideal Internalization on the Socio-Cultural Attitudes Towards Appearance Questionnaire (score ranging from 1 to 5 with higher scores indicating higher thin-ideal internalization) from post-intervention to follow-up

Time: one month (Month 2)

Description: Mean change in Dietary Restraint between post-intervention and follow-up

Measure: Mean Change in Dietary Restraint on the Dutch Eating Behaviour Questionnaire (score ranging from 1 to 5 with higher scores indicating higher dietary restraint) from post-intervention to follow-up

Time: one month (Month 2)

Description: Mean change in Anxiety between post-intervention and follow-up

Measure: Mean Change in Anxiety on the Hospital Anxiety and Depression Scale (score ranging from 0 to 21 with higher scores indicating higher anxiety) from post-intervention to follow-up

Time: one month (Month 2)

Description: Mean change in Depression between post-intervention and follow-up

Measure: Mean Change in Depression on the Hospital Anxiety and Depression Scale (score ranging from 0 to 21 with higher scores indicating higher depression) from post-intervention to follow-up

Time: one month (Month 2)

Description: Mean change in Eating Disorders Psychopathology between post-intervention and follow-up

Measure: Mean Change in Eating Disorders Psychopathology on the Eating Disorders Examination-Questionnaire (score ranging from 0 to 6 with higher scores indicating higher eating disorders psychopathology) from post-intervention to follow-up

Time: one month (Month 2)

Other Outcomes

Description: Mean of satisfaction with BP and HW assessed with four Likert scales after interventions

Measure: Mean of four 5-point Likert scales assessing program usefullness, help, understandability, usefulness of exercises (score from 1 to 5 with 5 indicating higher satisfaction) after interventions

Time: Month 1 or Month 2
7 Management of Body Weight Regulation, Symptoms of Low Energy Availability, Body Acceptance, Eating Disorders, and Sexual Harassment Among Female Martial Art Athletes, and Impact of COVID-19 on Training and Sport Participation

Athletes in martial arts compete in categories separated by body weight, hence, many athletes need to adjust their habitual body weight during periods with competition preparation. Athletes competing in weight sensitive sports are previously identified with an increased risk for symptoms of low energy availability and of disordered eating. The methods used for body weight regulation are varied, and athletes without professional competent support, are prone to rely on harmful methods. And of importance, female athletes respond more negatively to attempts of body weight reduction with regards to health effects. Athletes of martial art are not surrounded by the same professional competence seen in other organized sports within the international sport federations, and specifically health competence is lacking. Additionally, numbers of females competing in martial art have increased the last decade, but they still practice in a sport culture dominated by males; both with reference to the high number of male participants, and with reference to the coaches within this sport. Sports involving practice in intimate, physical interaction with coaches or opposing athletes, and in sports where clothing is minimal, may be a high risk of experiences of sexual harassment. There have been a few reports on harmful methods of body weight regulation within martial arts, however, little knowledge exists on the practice by female martial art athletes, and the related health effects. Information on experiences of sexual harassment have been sparse in sport generally, with very little knowledge from sports like martial arts specifically. This study aims to explore the practice of female martial art athletes on body weight regulation, recovery strategies, their body acceptance and symptoms of eating disorders, and any experiences of sexual harassment. Additionally, with regards to the recent onset of the Covid-19 pandemic, this study also explores the related experiences by the athletes on training- and eating routines.

NCT04559542
Conditions
  1. Body Weight Changes
  2. Eating Disorder Symptom
  3. Sexual Harassment
  4. Covid19
  5. RED S
MeSH:Body Weight Body Weight Changes Feeding and Eating Disorders

Primary Outcomes

Description: Evaluating intensity in symptoms of low energy availability, with one general score, one subscale measuring symptoms of menstrual irregularities, and one subscale measuring symptoms of gastrointestinal dysfunction; the three scales having cut-off scores of ≥8 , ≥4 and ≥2, with higher scorings indicating higher clinical severity.

Measure: Low energy availability for females questionnaire (LEAF-Q)

Time: Autumn 2020

Description: Measuring symptoms of eating disorders and frequency of eating disordered behavior, resulting in one total score, and four subscales (figure concern, weight concern, eating concern and eating restriction). A total score of ≥2.5 indicates high probability of having an eating disorder. Additionally, the scales measures frequency of disordered eating behavior, for which ≥1 episode per week of binge-eating and/or ≥1 episode per week of purging behavior, over a total period of ≥3 months, qualifies for an diagnosis of eating disorder.

Measure: Eating disorder examination questionnaire (EDE-q)

Time: Autumn 2020

Description: Reports on methods complied with, to achieve body weight reduction (Predefined answers, including an "other" option)

Measure: Body Weight regulation strategies, selfreported

Time: Autumn 2020

Description: Evaluates the level of body appreciation and acceptance. Questionnaire contains 10-items with a Likert scale ranging from 1 (Never) to 5 (Always), with a higher average score indicating a higher level of body appreciation.

Measure: Body appreciation scale (BAS-2)

Time: Autumn 2020

Secondary Outcomes

Description: Information on exercise frequency (number of sessions per week)

Measure: Exercise frequency, selfreported according to a designed questionnaire

Time: Autumn 2020

Description: Information on duration of sessions (minutes per session)

Measure: Exercise duration, selfreported according to a designed questionnaire

Time: Autumn 2020

Description: Information on motivation for material arts (reason for choosing the sport, and what level of performance one aims for)

Measure: Exercise motivation, selfreported according to a designed questionnaire

Time: Autumn 2020

Description: Information on the different physical activities performed (reports number of different sport activities undertaken during a typical week)

Measure: Exercise program variation, selfreported according to a designed questionnaire

Time: Autumn 2020

Description: Level of physical activity (counts/minute) objectively measured for seven consecutive days using the ActiGraph accelerometer (ActiGraph GT3x and GT3x+, Actigraph, LCC, Pensacola, Florida, USA)

Measure: Physical activity level, objectively measured

Time: Autumn 2020

Description: Four day diet registration by pictures and detailed notes, for analyses of energyintake.

Measure: Four day weighed diet registration; energyintake

Time: Autumn 2020

Description: Four day diet registration by pictures and detailed notes, for nutrient analyses. The outcomes will specifically be analysed for total intake of protein, carbohydrate, and fat (gram per kg bodyweight)

Measure: Four day weighed diet registration; nutrient intake

Time: Autumn 2020

Description: Four day diet registration by pictures and detailed notes, for nutrient analyses. The outcomes will be analysed for total intake of micronutrients specifically found to be in risk of insufficient intake among young norwegian females (calcium, vit-D, folic acid, iodine) and considering their specific needs due to high levels of physically activity (iron and vitamin C) (all given by mg nutrient consumed)

Measure: Four day weighed diet registration; nutrient intake

Time: Autumn 2020

Description: Questions on experiences of sexual harassment, current experience of such, and frequency of such episodes.

Measure: Experiences of sexual harassment

Time: Autumn 2020

Description: Questions on whether covid-19 changed their normal exercise and diet routines (yes/no), if this related to increased or decreased training volume or change in activity preferences. Additionally, whether the pandemic period has changed their energy intake (increased/decreased).

Measure: Effects from Covid-19 pandemic on exercise- and eating routines, designed questionnaire

Time: Autumn 2020

HPO Nodes


HPO

Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


HPO Nodes


Reports

Data processed on September 26, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  

Interventions

4,180 reports on interventions/drugs

MeSH

691 reports on MeSH terms

HPO

263 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook